The primary objective of this study is:
• To evaluate the long-term safety of fostamatinib in subjects with warm antibody autoimmune hemolytic anemia (wAIHA).
Кой може да участва
Inclusion Criteria:
1. Subject must be willing and able to give written informed consent by signing an IRB approved Informed Consent Form prior to undergoing any study-specific procedures.
2. Subject must have completed all 24 weeks of participation in the study C-935788-057.
Exclusion Criteria:
1\. Any subject who discontinued participation in Study C-935788-057 prior to Week 24.
Места на провеждане
16
Австралия (1)
Princess Alexandra Hospital - Cancer Trials Unit
Brisbane , Queensland
Belarus (1)
Vitebsk Regional Clinical Hospital
Vitebsk
България (1)
University Multiprofile Hospital for Active Treatment "Sveti Georgi" EAD, Plovdiv, Clinic of Medical oncology
Pleven
Чехия (1)
Fakultni nemocnice Brno Interni hematologicka a onkologicka klinika
Brno
Франция (1)
CHU de Bordeaux - GH Sud- Hôpital Haut Lévêque Service Médecine Interne et Maladies Infectieuses
Pessac
Georgia (1)
LTD Multiprofile Clinic Consilium Medulla
Tbilisi
Германия (1)
Universitätsklinikum Essen
Essen
Италия (1)
Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico, UO Ematologia
Milan
Нидерландия (1)
Academisch Medisch Centrum
Amsterdam
Норвегия (1)
Haukeland University Hospital
Bergen
Russia (1)
National Research Center for Hematology
Moscow
Сърбия (1)
Clinical Centre of Vojvodina, Clinic for Hematology
Novi Sad
Испания (1)
Hospital Vall d'Hebron
Barcelona
Ukraine (1)
City Clinical Hospital № 4, Hematology Center
Dnipro
Великобритания (1)
Roald Dahl Haemostasis and Thrombosis Centre, Royal Liverpool University Hospital, Liverpool University Hospitals NHS Foundation Trust
Liverpool
САЩ (1)
University of Southern California - Janice and Robert Hall Clinical Trials Biospecimen Laboratory
БГ
EN